GLPwatch
Papers (10389)
Page 152 of 174, ranked by citation count.
- Semaglutid: Ein wirksames Medikament zur Gewichtsabnahme.
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
- [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
- Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.
- In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
- Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
- Readability and understandability of online patient education on semaglutide.
- Long-Term Effectiveness of Once-Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real-World Study.
- Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.
- GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives.
- Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double‑Blind Single‑Centre Study.
- Semaglutide in people with HIV-associated lipohypertrophy.
- Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.
- Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study.
- GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation.
- [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
- The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
- Early Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.
- [Dulaglutide and liraglutide compared].
- Chemoenzymatic Synthesis of Rhamnolipid-Modified Exendin-4: A Dual Approach for Long-Acting Glycemic Control through Endogenous Antibody Recruitment and Albumin Interaction.
- [Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists].
- [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
- Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.
- Liraglutide for Adolescents with Obesity.
- [New hypoglycemic agents in type 2 diabetes].
- Real-world experience of semaglutide 2.4 mg in the US: a retrospective analysis of profiles, satisfaction, and treatment patterns in people with obesity and overweight.
- Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
- Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.
- Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2.
- Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
- Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years.
- Semaglutide ameliorates neuroinflammation and cognitive impairment in APP/PS1 mice.
- 9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model.
- Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
- Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.
- [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
- Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States.
- Semaglutide in Metabolic Medicine: <i>A Review on Clinical Applications and Emerging Therapeutics</i>.
- The effect of GLP-1 receptor agonists on autophagy: insights gathered from research evaluating neurodegenerative disorders with these agents.
- Comparative evaluation of liraglutide plus metformin combination therapy versus metformin monotherapy in patients with type 2 diabetes mellitus: A retrospective clinical study.
- Mirtazapine for gastrointestinal side effects of glucagon-like peptide-1 receptor agonist therapy in older adults.
- Calculating cost per event avoided using a composite number needed to treat.
- Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis.
- Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
- La metformine comme stabilisateur de poids après l’arrêt du sémaglutide ?
- Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.
- Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.
- Single-dose pharmacokinetics of sublingual semaglutide in rats.
- Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model.
- Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations.
- Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
- Comment on: "Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics" [Letter].
- Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.
- Illeum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.
- Blockbuster obesity drug leads to better health in people with HIV.
- [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].